Tags

Type your tag names separated by a space and hit enter

Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid.
Expert Opin Pharmacother. 2010 Apr; 11(5):731-8.EO

Abstract

IMPORTANCE OF THE FIELD

Optimization of lipid management is a crucial aspect in the treatment of cardiovascular disease. Currently, HMG-CO reductase inhibitors (statins) are a mainstay of therapy. While this class of drugs has proven efficacy at lowering low-density lipoprotein cholesterol (LDL-C), their effects on other important lipid parameters, such as high-density lipoprotein cholesterol (HDL-C) and triglycerides, are less robust.

AREAS COVERED IN THIS REVIEW

The current paper will address the significance of these secondary targets and review currently available therapies, including a new formulation of delayed-release fenofibric acid. A comprehensive MEDLINE search (1966 to September 2009) was performed.

WHAT THE READER WILL GAIN

The reader will gain a comprehensive review of the importance of secondary cholesterol targets, as well as the effectiveness of currently available therapies to address non-LDL-C. The role of the newly released fenofibric acid will also be addressed, as well as its potential use in combination therapy with a statin.

TAKE HOME MESSAGE

Adequate treatment of lipid parameters beyond LDL-C is an essential component in the treatment of dyslipidemia. The fibrate class of drugs has proven efficacy in improving secondary targets; however, concerns regarding severe myopathy and rhabdomyolysis have limited their combination with statins. Recently, a new fibrate derivative, fenofibric acid, has become available. Studies to date reflect a positive safety and tolerability profile when combined with statins. This may offer a new tool to address the important secondary cholesterol targets that are becoming increasingly recognized as important contributors to cardiovascular outcomes.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Schima SM
Department of Medicine, Division of Cardiology, Creighton University School of Medicine, Omaha, NE 68131, USA. Susan.Schima@cardiac.creighton.edu
Maciejewski SR
No affiliation info available
Hilleman DE
No affiliation info available
Williams MA
No affiliation info available
Mohiuddin SM
No affiliation info available

MeSH

Cardiovascular DiseasesCholesterol, LDLDelayed-Action PreparationsDrug Delivery SystemsDyslipidemiasFenofibrateHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic Agents

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

20210682

Citation

Schima, Susan M., et al. "Fibrate Therapy in the Management of Dyslipidemias, Alone and in Combination With Statins: Role of Delayed-release Fenofibric Acid." Expert Opinion On Pharmacotherapy, vol. 11, no. 5, 2010, pp. 731-8.
Schima SM, Maciejewski SR, Hilleman DE, et al. Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid. Expert Opin Pharmacother. 2010;11(5):731-8.
Schima, S. M., Maciejewski, S. R., Hilleman, D. E., Williams, M. A., & Mohiuddin, S. M. (2010). Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid. Expert Opinion On Pharmacotherapy, 11(5), 731-8. https://doi.org/10.1517/14656560903575639
Schima SM, et al. Fibrate Therapy in the Management of Dyslipidemias, Alone and in Combination With Statins: Role of Delayed-release Fenofibric Acid. Expert Opin Pharmacother. 2010;11(5):731-8. PubMed PMID: 20210682.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid. AU - Schima,Susan M, AU - Maciejewski,Stephanie R, AU - Hilleman,Daniel E, AU - Williams,Mark A, AU - Mohiuddin,Syed M, PY - 2010/3/10/entrez PY - 2010/3/10/pubmed PY - 2010/6/18/medline SP - 731 EP - 8 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 11 IS - 5 N2 - IMPORTANCE OF THE FIELD: Optimization of lipid management is a crucial aspect in the treatment of cardiovascular disease. Currently, HMG-CO reductase inhibitors (statins) are a mainstay of therapy. While this class of drugs has proven efficacy at lowering low-density lipoprotein cholesterol (LDL-C), their effects on other important lipid parameters, such as high-density lipoprotein cholesterol (HDL-C) and triglycerides, are less robust. AREAS COVERED IN THIS REVIEW: The current paper will address the significance of these secondary targets and review currently available therapies, including a new formulation of delayed-release fenofibric acid. A comprehensive MEDLINE search (1966 to September 2009) was performed. WHAT THE READER WILL GAIN: The reader will gain a comprehensive review of the importance of secondary cholesterol targets, as well as the effectiveness of currently available therapies to address non-LDL-C. The role of the newly released fenofibric acid will also be addressed, as well as its potential use in combination therapy with a statin. TAKE HOME MESSAGE: Adequate treatment of lipid parameters beyond LDL-C is an essential component in the treatment of dyslipidemia. The fibrate class of drugs has proven efficacy in improving secondary targets; however, concerns regarding severe myopathy and rhabdomyolysis have limited their combination with statins. Recently, a new fibrate derivative, fenofibric acid, has become available. Studies to date reflect a positive safety and tolerability profile when combined with statins. This may offer a new tool to address the important secondary cholesterol targets that are becoming increasingly recognized as important contributors to cardiovascular outcomes. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/20210682/Fibrate_therapy_in_the_management_of_dyslipidemias_alone_and_in_combination_with_statins:_role_of_delayed_release_fenofibric_acid_ DB - PRIME DP - Unbound Medicine ER -